Cochrane · systematic review · CD011395
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
Taylor, AM, Chan, DLok Hang, Tio, M, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 1 · 25%High 2 · 50%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PARPi‐containing regimen compared to non‐PARPi regimen for locally advanced or metastatic breast cancer
Population: locally advanced or metastatic breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival** PARPi‐containing regimen vs non‐PARPi regimen | HR 0.84 [0.76, 1] | 4 studies · 1435 participants | High |
Progression Free Survival** PARPi‐containing regimen vs non‐PARPi regimen | HR 0.63 [0.56, 0.71] | 5 studies · 1474 participants | High |
Response Rate PARPi‐containing regimen vs non‐PARPi regimen | RR 1.39 [1.24, 1.54] | 5 studies · 1185 participants | Low Downgraded: risk of bias |
Grade ≥3 AEs PARPi‐containing regimen vs non‐PARPi regimen | RR 0.98 [0.91, 1.04] | 5 studies · 1443 participants | Moderate Downgraded: risk of bias |